{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"en-studie-av-plx8394-som-monoterapi-hos-pasienter-med-avanserte-inoperable-solide-svulster","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/nb\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"En studie av PLX8394 som monoterapi hos pasienter med avanserte, inoperable solide svulster"},"content":{"rendered":"<p><strong>Form\u00e5let med studien:<\/strong>&nbsp; M\u00e5let med denne kliniske studien er \u00e5 finne ut hvordan PLX8394 kan p\u00e5virke kreftceller med mutasjoner i BRAF-genet.  PLX8394 er utviklet for \u00e5 blokkere mutasjoner i BRAF.  Disse mutasjonene kan for\u00e5rsake kreft og vekst av kreftceller.\u00a0 Ved \u00e5 blokkere disse mutasjonene kan legemidlet drepe kreftcellene med mutasjonen og\/eller hindre svulsten i \u00e5 vokse.<\/p>\n<p><strong>Sponsor:<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Kontaktopplysninger for rettssaken:<\/strong>&nbsp; Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org eller Filip Janku; 713-563-1930; FJanku@mdanderson.org<\/p>\n<p><strong>\u00d8nsket pasientmedvirkning:<\/strong>&nbsp; ECD-pasienter over 18 \u00e5r.<\/p>\n<p><strong>Kjente sentre som tar imot ECD-pasienter i studien:<\/strong>&nbsp; MD Anderson, Houston, Texas<\/p>\n<p><strong>ClinicalTrials.gov-identifikator:<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}